Boulegeris Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Boulegeris Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-9,425	Closed	-$202K	–	51
2016 Q1	$202K	Buy	9,425 +50	+0.5%	+$1.12K	0.14%	51
2015 Q4	$296K	Sell	9,375 -8,865	-49%	-$313K	0.21%	40
2015 Q3	$628K	Buy	18,240 +825	+5%	+$24.9K	0.48%	34
2015 Q2	$548K	Buy	17,415 +915	+6%	+$27K	0.39%	35
2015 Q1	$484K	Buy	16,500 +5,425	+49%	+$127K	0.36%	37
2014 Q4	$205K	Buy	+11,075	New	+$187K	0.16%	45

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Boulegeris Investments's MRTX Position: Q2 2016 in Review

Boulegeris Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2016, closing a stake of 9,425 shares — an estimated $202K sold.

Boulegeris Investments first reported a position in MRTX in Q4 2014 and held it in 6 quarters. The position peaked at $628K in Q3 2015. 72 funds tracked by Wall St. Rank hold MRTX as of Q2 2016.

Boulegeris Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Boulegeris Investments sold 9,425 Mirati Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $202K.
Boulegeris Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2014 and held it in 6 quarters.
Boulegeris Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $628K in Q3 2015.
72 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Boulegeris Investments's 13F filing for Q2 2016, filed 12 Jul 2016.